Immunocore Holdings plc
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
IMCR | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 90 PARK DRIVE, OXFORDSHIRE
- Website:
- https://www.immunocore.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Immunocore Holdings plc is a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies. The company's proprietary ImmTAX® (Immune mobilizing monoclonal TCRs Against X disease) technology platform is engineered to harness the body's immune system. This modular technology activates T cells to recognize and destroy diseased cells in cancer and infectious diseases, or it can suppress the immune response in autoimmune conditions. Immunocore has successfully developed and commercialized the world's first approved TCR therapy and maintains a diverse pipeline of clinical and pre-clinical programs across its core therapeutic areas.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Immunocore Holdings plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immunocore Holdings plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immunocore Holdings plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
